Seth Lerner, MD on Technical Aspects to Delivering the Drug in Urothelial Cancer @bcmhouston

Seth Lerner, MD on Technical Aspects to Delivering the Drug in Urothelial Cancer @bcmhouston

User Photo
Cancer-News

4 months
6 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer.

______________

Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year.

"Urothelial cancer refers to a cancer of the lining of the urinary system. While about 9 of 10 urothelial cancers arise in the bladder (lower tract), a small subset arises in the upper tract, in the lining of the kidney or the ureter, the long, thin tube that connects that kidney to the bladder," said corresponding and senior author Dr. Seth P. Lerner, professor of urology and Beth and Dave Swalm Chair in Urologic Oncology at Baylor.

Read here: https://www.eurekalert.org/pub_releases/2020-04/bcom-iao042920.php

Up Next Autoplay